We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

216 hedge funds and large institutions have $882M invested in Immunogen Inc in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 81 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

378% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $912K

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% less funds holding

Funds holding: 217216 (-1)

4% less capital invested

Capital invested by funds: $922M → $882M (-$39.6M)

23% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 81

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
216
Holders Change
-1
Holders Change %
-0.46%
% of All Funds
3.64%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
25
Increased
62
Reduced
81
Closed
23
Calls
$4.36M
Puts
$912K
Net Calls
+$3.45M
Net Calls Change
-$1.95M
Name Holding Trade Value Shares
Change
Change in
Stake
QF
26
QVT Financial
New York
$6.19M
RPAM
27
Rhenman & Partners Asset Management
Sweden
$5.4M -$977K -225,000 -16%
PAM
28
Panagora Asset Management
Massachusetts
$5.22M -$54.9K -12,642 -1%
SI
29
Sofinnova Investments
California
$5.13M -$1.25M -287,381 -20%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$4.96M -$47.7M -10,972,360 -91%
CS
31
Candriam SCA
Luxembourg
$4.75M +$4.59M +1,056,439 New
LOAMS
32
Lombard Odier Asset Management (Switzerland)
Switzerland
$4.52M -$5.52M -1,270,783 -56%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$4.4M -$1.19M -274,750 -22%
N
34
Nuveen
North Carolina
$4.31M -$5.35M -1,231,506 -56%
SAM
35
Sectoral Asset Management
Quebec, Canada
$4.23M +$267K +61,400 +7%
SBH
36
Segall Bryant & Hamill
Illinois
$3.85M +$45.5K +10,483 +1%
Goldman Sachs
37
Goldman Sachs
New York
$3.81M +$726K +167,137 +25%
Citigroup
38
Citigroup
New York
$3.61M +$2.69M +619,203 +336%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$3.37M -$456K -104,868 -12%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$3.36M -$226K -52,040 -7%
Primecap Management
41
Primecap Management
California
$3.28M -$124K -28,500 -4%
Wells Fargo
42
Wells Fargo
California
$2.89M -$776K -178,669 -22%
HM
43
HealthCor Management
New York
$2.25M -$3.52M -810,340 -62%
AllianceBernstein
44
AllianceBernstein
Tennessee
$2.16M +$833K +191,657 +66%
CM
45
CM Management
Florida
$2.14M +$109K +25,000 +6%
Swiss National Bank
46
Swiss National Bank
Switzerland
$2.1M -$50.4K -11,600 -2%
Allianz Asset Management
47
Allianz Asset Management
Germany
$1.89M +$957K +220,185 +110%
SCM
48
Silverarc Capital Management
Massachusetts
$1.87M -$993K -228,521 -35%
Fisher Asset Management
49
Fisher Asset Management
Washington
$1.72M +$3.14K +722 +0.2%
DCM
50
Driehaus Capital Management
Illinois
$1.49M +$352K +80,909 +32%

IMGN Hedge Fund Activity: Q2 2022 in Review

216 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2022, worth a combined $882M — down 4.3% from $922M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new IMGN positions and 23 closed out — a net gain of 2 holders — while 62 added to existing stakes and 81 trimmed.

The largest buyer was Deerfield Management, adding an estimated $50.2M. The largest seller was Fidelity Investments, cutting an estimated $47.7M.

  • 216 institutional investors held Immunogen Inc (IMGN) as of Q2 2022, down from 217 in Q1 2022.
  • Funds reported $882M of Immunogen Inc stock for Q2 2022, down 4.3% quarter-over-quarter.
  • 25 funds opened new Immunogen Inc positions in Q2 2022 and 23 closed out, a net change of +2 holders.
  • The largest Immunogen Inc buyer in Q2 2022 was Deerfield Management, an estimated $50.2M added.
  • The largest Immunogen Inc seller in Q2 2022 was Fidelity Investments, an estimated $47.7M sold.

Based on aggregated 13F filings for Q2 2022.